Despite a surge in FDA-cleared radiology AI tools, very few qualify for reimbursement due to lack of supporting clinical studies.
Key Details
- 1Radiology comprises roughly 80% of all FDA-cleared medical AI algorithms.
- 2Only one CPT category 1 payment code for newer AI tools exists today; a second will be added in January 2026.
- 3Both reimbursement codes are specific to cardiac imaging AI applications.
- 4Hundreds of approved algorithms lack reimbursement due to insufficient clinical evidence of patient benefit.
- 5Experts attribute the problem to a disconnect between regulatory clearance and payment policy.
Why It Matters
Without reimbursement, the financial incentives for clinical adoption of imaging AI are limited, slowing broader deployment of these technologies. Bridging the gap between regulatory approval and payment is critical for real-world impact of AI in radiology.
Source
Radiology Business
Related News
•Radiology Business
Radiology Societies Urge Patient Safety in FDA Generative AI Regulation
RSNA and ACR call for patient safety and ongoing monitoring as the FDA considers regulations for generative AI in radiology.
•AuntMinnie
LLMs Rarely Recommend Unnecessary Imaging, Except for Thyroid Ultrasound
Large language models seldom over-recommend imaging, but thyroid ultrasound guidance shows substantial discrepancies.
•AuntMinnie
HPI Rebuts AI's Supposed Impact on Radiology Workforce Shortage
Harvey L. Neiman HPI challenges recent claims that AI has lessened the radiology workforce burden, citing evidence of rising workloads and imaging volumes.